Apollomics股价因第二阶段vebreltini数据上涨30%

Apollomics (NASDAQ:APLM) stock rallied 30% in morning trading Tuesday after the company announced positive Phase 2 data for its oncology drug candidate vebreltinib.

The preliminary data showed a 43% objective response rate in a cohort of patients with non-CNS MET fusion solid tumors. Median overall survival was 12.4 months, according to a statement.

Based on the data, Apollomics is evaluating opportunities for further development of the therapy in patients with MET fusions.